GNW: Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish
Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
Biogen to acquire Nightstar Therapeutics for $25.50 per share
Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that would otherwise lead to blindness
Nightstar has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs
Lead asset NSR-REP1 is in Phase 3 development for cho...